成人结核性脑膜炎大剂量口服利福平试验
这项双盲、随机、安慰剂对照试验在印度尼西亚、南非和乌干达纳入499例成人结核性脑膜炎患者,比较利福平35 mg/kg(大剂量组)与10 mg/kg(标准剂量组)联合标准抗结核治疗对6个月死亡率的影响。结果显示大剂量组6个月死亡率44.6% vs 标准剂量组40.7%,HR 1.17(95%CI 0.89-1.54;P=0.25),无获益证据,且不能排除潜在危害。
要点
- 大剂量利福平组6个月死亡率44.6%,标准剂量组40.7%,差异无统计学意义。
- 大剂量组与标准剂量组6个月死亡HR为1.17(95%CI 0.89-1.54;P=0.25)。
- 大剂量组药物性肝损伤发生率8.0%,标准剂量组4.4%,无肝损伤相关死亡。
核心结论
- 在结核性脑膜炎患者中,未观察到大剂量利福平的有益效应证据,且不能排除潜在有害效应。
研究设计与样本
- 双盲、随机、安慰剂对照临床试验,在印度尼西亚、南非和乌干达纳入成人结核性脑膜炎患者,包括HIV合并感染和非合并感染者。
- 意向治疗人群共499例,其中大剂量组249例、标准剂量组250例;304例(60.9%)为HIV感染者,428例(85.8%)为确诊或很可能结核性脑膜炎。
- 两组均接受标准每日异烟肼、利福平(10 mg/kg)、乙胺丁醇和吡嗪酰胺,大剂量组额外加用利福平使累积剂量达35 mg/kg,标准剂量组加用匹配安慰剂,持续8周;此后两组继续标准治疗至9-12个月疗程结束。
- 主要结局为6个月死亡率。
主要发现
- 6个月随访期间,大剂量组109例死亡(Kaplan-Meier估计44.6%),标准剂量组100例死亡(Kaplan-Meier估计40.7%)(HR 1.17;95%CI 0.89-1.54;P=0.25)。
- 6个月内死亡者中,大剂量组中位死亡时间13天(四分位距4-39),标准剂量组24天(四分位距6-56)。
- 药物性肝损伤发生于大剂量组8.0%和标准剂量组4.4%的参与者,但无药物性肝损伤相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervous system penetration. Whether high-dose rifampin could improve survival outcomes is unknown. METHODS: We performed a double-blind, randomized, placebo-controlled clinical trial involving adults with tuberculous meningitis in Indonesia, South Africa, and Uganda. We assigned persons with and those without human immunodeficiency virus (HIV) coinfection to receive standard daily isoniazid, rifampin (at a dose of 10 mg per kilogram of body weight), ethambutol, and pyrazinamide plus either additional rifampin (for a cumulative dose of 35 mg per kilogram; high-dose group) or matched placebo (standard-dose group) for 8 weeks; participants in both groups received standard therapy for the remainder of the 9-to-12-month treatment course. The primary outcome was 6-month mortality. RESULTS: A total of 499 participants were included in the intention-to-treat population (249 randomly assigned to the high-dose group and 250 to the standard-dose group), of whom 304 (60.9%) were persons living with HIV and 428 (85.8%) had definite or probable tuberculous meningitis. During 6 months of follow-up, 109 participants (Kaplan-Meier estimate, 44.6%) in the high-dose group and 100 participants (Kaplan-Meier estimate, 40.7%) in the standard-dose group died (hazard ratio, 1.17; 95% confidence interval, 0.89 to 1.54; P = 0.25). Among the participants who died within 6 months, the median time to death was 13 days (interquartile range, 4 to 39) in the high-dose group and 24 days (interquartile range, 6 to 56) in the standard-dose group. Drug-induced liver injury occurred in 8.0% of the participants in the high-dose group and in 4.4% of those in the standard-dose group, but no deaths from drug-induced liver injury occurred. CONCLUSIONS: Among persons with tuberculous meningitis, no evidence of beneficial effect from high-dose rifampin was observed, and the potential for a harmful effect cannot be ruled out. (Funded by the U.K. Medical Research Council and others; ISRCTN Registry number, ISRCTN15668391.).
引用
- Meya DB, Cresswell FV, Dai B, et al. Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. N Engl J Med. 2025. PMID: 41406445. doi:10.1056/NEJMoa2502866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。